Advertisement

Topics

ILC 2018: Allergan’s cenicriviroc shows continued fibrosis response in NASH patients in two year extended study

05:25 EDT 17 Apr 2018 | Net Resources International

Evidence that Allergan’s Phase III drug candidate, cenicriviroc, may benefit non-alcoholic steatohepatitis (NASH) patients was presented at the 2018 International...
Read More...

The post ILC 2018: Allergan’s cenicriviroc shows continued fibrosis response in NASH patients in two year extended study appeared first on Drug Development Technology.

Original Article: ILC 2018: Allergan’s cenicriviroc shows continued fibrosis response in NASH patients in two year extended study

NEXT ARTICLE

More From BioPortfolio on "ILC 2018: Allergan’s cenicriviroc shows continued fibrosis response in NASH patients in two year extended study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...